Facebook
Twitter
LinkedIn

MPT Product Development Database

This database includes MPT products that are currently available, as well as MPT products in active development. The database outlines detailed product information and can be searched to display products by desired criteria as selected from the drop-down boxes or by entering a keyword in the search box. Click on the product name to access detailed information on each product. Please note there are other MPT candidates not listed that may move forward pending funding. Click here to learn more about the inclusion criteria and information update methodology.
Know of an MPT product not included in this database or have updated information for listed products? Let us know here!
Click on the table for MPT products in the development pipeline by indication combination.
Hormonal/Non-HormonalDelivery RouteDelivery MethodDevelopment Stage
       
IndicationProduct DeveloperProduct Sponsor/FundingActive Ingredient
       
Key Word Search   
       

25 product(s) found



Tenofovir + Levonorgestrel IVR

MPT in Development

Development Stage:
Clinical – Phase 2 Trial (C2)
Hormonal/Non-Hormonal:
Hormonal
Delivery Route & Method:
Topical - Intravaginal Ring (IVR)
Mechanism of Action:
nucleoside analogue reverse transcriptase inhibitor (NRTI), progestin
Developer:
  • CONRAD
    • Funding:
  • Centers for Disease Control and Prevention (CDC)
  • U.S. Agency for International Development (USAID)
    • Funding Mechanism:
    USAID: Cooperative Agreement
    Past Funding:
    Bill & Melinda Gates Foundation
    NIH: Interagency Agreements to USAID
    Active Ingredient:
  • Levonorgestrel
  • Tenofovir (TFV)
    •
    Product Indications:
  • HIV
  • HSV-2
  • Pregnancy
    •
    Description:
    Polyurethane, dual-reservoir ring designed for 3 months of continuous use, or with up to 3 days intermittent removal. The first-in-women Phase I trial (CONRAD-128) completed in 2016 and successfully met all performance benchmarks. An expanded Phase I study (CONRAD-138) was completed in early 2019; results expected mid-2020. A first-in-kind study to evaluate MPT IVRs in Africa, the CDC Kisumu Combined Ring Study (CONRAD B17-144) was completed in late 2019; results expected in late 2020.
    Useful Links:
    https://clinicaltrials.gov/ct2/show/NCT02235662?cond=tenofovir+levonorgestrel&draw=2&rank=2
    https://clinicaltrials.gov/ct2/show/NCT03279120?cond=tenofovir+levonorgestrel&draw=2&rank=1
    https://clinicaltrials.gov/ct2/show/NCT03762382?cond=tenofovir+levonorgestrel&draw=2&rank=1


    IMPT Secretariat
    1750 Howe Avenue, Suite 550
    Sacramento, CA 95825
    IMPT@cami-health.org

    The Initiative for Multipurpose Prevention Technologies (IMPT) is a project of CAMI Health, an organization dedicated to advancing the comprehensive sexual and reproductive health of women and girls worldwide. CAMI Health is housed at the Public Health Institute (PHI).

    © Copyright 2020, Public Health Institute / CAMI Health / IMPT Secretariat. All rights reserved.